Synthesis and biological evaluation of ethacrynic acid derivatives bearing sulfonamides as potent anti-cancer agents. 2020

Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
Euromed Research Center, Euromed Institute of Technology, Euromed University of Fes (UEMF)-Route de Meknès, 30000 Fes, Morocco; Institut de Chimie Organique et Analytique, Université d'Orléans, UMR CNRS 7311, BP 6759, Orléans cedex 2 54067, France.

A series of ethacrynic acid (2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid) (EA, Edecrin) containing sulfonamides linked via three types of linkers namely 1,2-ethylenediamine, piperazine and 4-aminopiperidine was synthesized and subsequently evaluated in vitro against HL60 and HCT116 cancer cell lines. All the EA analogs, excluding 6a and 6c, showed anti-proliferative activity with IC50s in the micromolar range (less than 4 uM). Three derivatives 6b, 7b and 7e were selected for their interesting dual activity on HL60 cell line in order to be further evaluated against a panel of cancer cell lines (HCT116, A549, MCF7, PC3, U87-MG and SKOV3) as well as on MRC5 as a normal cell line. These compounds displayed IC50 values in nanomolar range against A549, MCF7, PC3 and HCT116 cell lines, deducing the discovery that piperazine or 4-aminopiperidine is the linker's best choice to develop EA analogs with highly potent anti-proliferative activities own up to 24 nM. Besides, in terms of selectivity, those linkers are more suitable offering safety ratios of up to 63.8.

UI MeSH Term Description Entries
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004976 Ethacrynic Acid A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. Edecrin,Etacrynic Acid,Ethacrinic Acid,Ethacrynate Sodium,Ethacrynic Acid, Sodium Salt,Hydromedin,Acid, Etacrynic,Acid, Ethacrinic,Acid, Ethacrynic,Sodium, Ethacrynate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
March 2015, European journal of medicinal chemistry,
Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
August 2012, Archiv der Pharmazie,
Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
December 2014, Bioorganic & medicinal chemistry letters,
Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
May 2017, Bioorganic & medicinal chemistry letters,
Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
September 2011, Bioorganic & medicinal chemistry,
Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
June 2015, Bioorganic & medicinal chemistry letters,
Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
August 2013, Bioorganic & medicinal chemistry letters,
Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
August 2013, European journal of medicinal chemistry,
Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
November 2016, Bioorganic & medicinal chemistry letters,
Abdelmoula El Abbouchi, and Nabil El Brahmi, and Marie-Aude Hiebel, and Jérôme Bignon, and Gérald Guillaumet, and Franck Suzenet, and Saïd El Kazzouli
December 2019, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!